Lilly sues Indianapolis clinic for selling split doses of popular weight-loss drugs
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
Eli Lilly and Co.
-
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More -
UPDATE: Lilly reports robust Q4, full-year earnings
Lilly’s fourth-quarter earnings, released before the market opened Thursday, surpassed analysts’ expectations by millions.
Read More -
Roche gets FDA clearance for test of emerging cardiovascular disease risk factor
Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.
Read More
Articles
Skyrocketing cost of weight-loss drugs has state Medicaid programs looking for solution
At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not one of them.
Trump administration nixes plan to cover anti-obesity drugs through Medicare
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Purdue president: Universities must explore private alternatives to federal funding
Amid uncertainty around federal research funding, universities must explore private support, Purdue University President Mung Chiang told an tech industry group on Tuesday.
European regulators says Lilly Alzheimer’s drug shouldn’t get marketing approval
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it recommended refusing marketing authorization for it.
Lilly adds online education, care services for Alzheimer’s to LillyDirect platform
The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for early diagnosis and intervention.
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
Lilly cuts undisclosed number of jobs, ‘nothing large scale’
The reductions come at a time of significant growth overall for Lilly. and soon after the announcement of plans to build new manufacturing facilities at four yet-to-be-named U.S. locations.
LEAP spending nears $1B with projected budget shielded, investigation finds
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic development projects Indiana has attempted. But the agency’s structure obscures its spending and who benefits.
Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.
Roughly 16 million people—that’s 6 percent of American adults—are taking GLP-1 weight-loss drugs, and that number is growing rapidly. Their collective purchasing power has the potential to profoundly reshape the economy.
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
Trump casts psychiatric and weight-loss drugs as threats to children
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
Lebanon planning board to review designs for Lilly’s $4.5B foundry at LEAP District
IMAGE GALLERY: The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians.
Could obesity drugs help with alcohol cravings? New study suggests potential.
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not just for food, but also for tobacco and alcohol.
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.’s Omvoh, a new therapy to treat Chron’s disease and ulcerative colitis, is the company’s latest step into the treatment of gastrointestinal diseases.
New life sciences consortium aims to give Indiana researchers better access to health data
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially helping Eli Lilly and Co. and other companies develop new medicines more quickly.
Sweeping review looks at effect of weight-loss drugs on 175 conditions
The research is the first to attempt to comprehensively investigate the impact—both good and bad—of the GLP-1 weight-loss drugs on the human body.
Lilly shares fall midday on lower fourth quarter revenue guidance
The company expects fourth-quarter revenue to be about $13.5 billion.
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.